抗beta Amyloid (MOAB-2)抗体 | Anti-beta Amyloid (MOAB-2) Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

	Genetic Strategies Validation. Immunohistochemistry: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - IHC analysis of beta Amyloid on normal mouse brain (left) and 5xFAD mouse brain (right) using DAB with hematoxylin counterstain. The MOAB-2 antibody was used at 1:20 on normal mouse brain and at 1:400 on 5xFAD mouse brain.
	Immunohistochemistry-Paraffin: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - IHC analysis of a formalin fixed paraffin embedded tissue section of human brain (Alzheimers disease, hippocampus) using 1:200 dilution of anti-beta Amyloid antibody (clone MOAB-2). The staining was developed with HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This beta Amyloid antibody specifically stained the cells with Abeta 42/ Abeta aggregates while the normal cells were negative for abeta peptide.
	Western Blot: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - Western blot analysis in cell lysates from HEK-APP SWE/BACE1 cells probed with an antibody against the C-terminus of APP (Lanes 1 and 2) and beta Amyloid (MOAB-2, Lanes 3 and 4). Beta Amyloid (MOAB-2) does not detect APP (from PMID: 22423893).
	Western Blot: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - Analysis of beta Amyloid (MOAB-2) antibody in 1) 100 pmole beta Amyloid 42, 2) 5xFAD mouse brain homogenate Repetition 1 and 3) 5xFAD mouse brain homogenate Repetition 2.
	Immunocytochemistry/Immunofluorescence: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - Immunofluorescent detection of beta Amyloid with MOAB-2 in the subiculim of 1-, 2- and 4- month old 5xFAD mice. Scale bar 20 um (from PMID: 22423893).
	Immunohistochemistry-Paraffin: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - IHC analysis of a formalin fixed paraffin embedded tissue section of human brain (Alzheimers disease, hippocampus) using 1:40 dilution of anti-beta Amyloid antibody (clone MOAB-2). The staining was developed with HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This beta Amyloid antibody specifically stained the cells with Abeta 42/ Abeta aggregates while the normal cells were negative for abeta peptide.

目次に戻る

Background

Beta Amyloid, also known as Abeta, is a peptide that varies in length from 39 to 43 amino acids and is processed from the Amyloid precursor protein (APP). Beta Amyloid is known as the main component of amyloid plaques, which are deposits found in the brains of patients with Alzheimer's disease. The form(s) of beta Amyloid associated with the pathology characteristic of Alzheimer's disease still remains unclear. Currently, controversy exists as to the existence of intraneuronal beta Amyloid. Research indicates that intraneuronal beta Amyloid accumulation may be an important proximal neurotoxic event in the pathogenesis of Alzheimer's disease. Many commercially available beta Amyloid antibodies cross react with APP or APP C-terminal fragments. This MOAB-2 antibody is specific for beta Amyloid but not APP. MOAB-2 is a pan-specific beta Amyloid antibody that detects unaggregated, oligomeric and fibrillar forms of beta Amyloid. This is important because beta Amyloid is known to aggregate and form a variety of potentially toxic conformations. MOAB-2 displays strong extracellular beta Amyloid immunoreactivity, and so detects classic plaque pathology. MOAB-2 is selective for Abeta 42 over Abeta 40. This is also an advantage as the 42 amino acid form of beta Amyloid is likely the toxic form. MOAB-2 demonstrates strong intraneuronal immunoreactivity in both human and beta Amyloid-Tg mouse tissue and has the potential to aid future research into the functional importance of intraneuronal beta Amyloid.

目次に戻る